ReviewExpert reviews in molecular medicine2015
Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.
Review in Expert reviews in molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 72 citations in OpenAlex.
- The LVI Component Hypothesis: the lymphatic-to-vascular invasion ratio as an enrichment biomarker for therapy with PD-L1×VEGF-A bispecific antibodies.Frontiers in immunology · 2026Article
- Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches.Biomarker research · 2025Review
- Identification of endothelial INSR as an osteosarcoma-related biomarker and therapeutic target based on weighted gene co-expression network analysis.Discover oncology · 2025Article
- Transforming Cancer Therapy: Unlocking the Potential of Targeting Vascular and Stromal Cells in the Tumor Microenvironment.Cancer research · 2025Review
- The role of tumor microenvironment and self-organization in cancer progression: Key insights for therapeutic development.BioImpacts : BI · 2025Review
- Microphysiological Systems for Cancer Immunotherapy Research and Development.Advanced biology · 2024Review
- A microfluidic organ-on-a-chip: into the next decade of bone tissue engineering applied in dentistry.Future science OA · 2023Review
- Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy.Life medicine · 2023Review
- Article
- Tumor Necrosis Factor-Mediators of inflammation · 2023Article
- The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting.Expert opinion on therapeutic targets · 2022Article
- MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin.Archives of dermatological research · 2022Article
- Article
- Haploinsufficiency of the lysosomal sialidase NEU1 results in a model of pleomorphic rhabdomyosarcoma in mice.Communications biology · 2022Article
- Catulin reporter marks a heterogeneous population of invasive breast cancer cells with some demonstrating plasticity and participating in vascular mimicry.Scientific reports · 2022Article
- Systems biology of angiogenesis signaling: Computational models and omics.WIREs mechanisms of disease · 2022Review
- Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels.BMC biology · 2022Article
- Lymphatic Tissue and Organ Engineering for In Vitro Modeling and In Vivo Regeneration.Cold Spring Harbor perspectives in medicine · 2022Article
- Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies.Frontiers in pharmacology · 2022Review
- The Lymphatic System in Breast Cancer: Anatomical and Molecular Approaches.Medicina (Kaunas, Lithuania) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Tumour and organ microenvironments are crucial for cancer progression and metastasis. Crosstalk between multiple non-malignant cell types in the microenvironments and cancer cells promotes tumour growth and metastasis. Blood and lymphatic endothelial cells (BEC and LEC) are two of the components in the microenvironments. Tumour blood vessels (BV), comprising BEC, serve as conduits for blood supply into the tumour, and are important for tumour growth as well as haematogenous tumour dissemination. Lymphatic vessels (LV), comprising LEC, which are relatively leaky compared with BV, are essential for lymphogenous tumour dissemination. In addition to describing the conventional roles of the BV and LV, we also discuss newly emerging roles of these endothelial cells: their crosstalk with cancer cells via molecules secreted by the BEC and LEC (also called angiocrine and lymphangiocrine factors). This review suggests that BEC and LEC in various microenvironments can be orchestrators of tumour progression and proposes new mechanism-based strategies to discover new therapies to supplement conventional anti-angiogenic and anti-lymphangiogenic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.